Cidara Therapeutics, Inc. (CDTX) NASDAQ
221.38
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Cidara Therapeutics, Inc.
Address
6310 Nancy Ridge Drive
San Diego, CA 92121
United States of America (the)
Phone
858 752 6170
Website
Sector
Healthcare
Industry
Biotechnology
Employees
38
First IPO Date
April 15, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Jeffrey L. Stein | President, Chief Executive Officer & Executive Director | 1.1M | 1955 |
| Kevin Forrest | Founder & Chief Strategy Officer | 333,313 | 1977 |
| Preetam Shah | Principal Accounting Officer | 577,850 | 1973 |
| Shane Ward | Chief Operating Officer & Corporate Secretary | 620,940 | 1975 |
| Nicole Davarpanah | Chief Medical Officer | 664,600 | N/A |
| Leslie Tari | Chief Scientific Officer | 688,050 | 1967 |
| Frank L. Karbe | Chief Financial Officer | 0 | 1968 |
| Jim Beitel | Chief Business Officer | 0 | N/A |
| Allison Lewis SPHR | Senior Vice President of People & Culture | 0 | N/A |
| Corrina Pavetto | Senior Vice President of Clinical Development | 0 | N/A |
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
